Skip to main navigation

Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

  • Read more about Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

  • Read more about Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Publication relating to transparency notifications

  • Read more about Publication relating to transparency notifications

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

  • Read more about Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

Publication relating to transparency notifications

  • Read more about Publication relating to transparency notifications

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Nyxoah Announces Closing of Underwritten Public Offering

  • Read more about Nyxoah Announces Closing of Underwritten Public Offering

Nyxoah Announces Pricing of $95 Million Underwritten Public Offering

  • Read more about Nyxoah Announces Pricing of $95 Million Underwritten Public Offering

Pagination

  • Page 1
  • Next page ››
Subscribe to Regulated information